Level C· Early human research exploring benefitsProspective StudyEurope PMCOpen access

Alterations of SOCS1 and SOCS3 transcript levels, but not promoter methylation levels in subcutaneous adipose tissues in obese women

Emamgholipour S., Esmaeili F., Shabani M., Hasanpour SZ., Pilehvari M., Zabihi-Mahmoudabadi H.

Prospective Study with a reported sample of 24 on Type 2 Diabetes, published in BMC Endocr Disord (2023) — summary generated from the PubMed abstract.

Open my reading list
Level C· Early human research exploring benefitsEvidence level of this study

Early human evidence such as case series or small samples is exploring possible benefits.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Prospective Study
Journal
BMC Endocr Disord (2023)
Reported sample size
24
Source database
Europe PMC
PMID
36609306
PMCID
PMC9817302
DOI
10.1186/s12902-022-01247-5
Citations
5

Abstract (original English)

Background Animal model studies suggest that change in the members of the suppressor of the cytokine signaling (SOCS) family (mainly SOCS1 and SOCS3) is linked to the pathogenesis of obesity-related metabolic disorders. Moreover, epigenetic modification is involved in the transcriptional regulation of the SOCS gene family. Here, we aimed to evaluate the mRNA expression as well as gene promoter methylation of SOCS1 and SOCS3 in subcutaneous adipose tissue (SAT) from obese women compared to normal-weight subjects. We also intend to identify the possible association of SOCS1 and SOCS3 transcript levels with metabolic parameters in the context of obesity. Methods This study was conducted on women with obesity (n = 24) [body mass index (BMI) ≥ 30 kg/m 2 ] and women with normal-weight (n = 22) (BMI 2 ). Transcript levels of SOCS1 and SOCS3 were evaluated by real-time PCR in SAT from all participants. After bisulfite treatment of DNA, methylation-specific PCR was used to assess the putative methylation of 10 CpG sites in the promoter of SOCS1 and 13 CpG sites in SOCS3 in SAT from women with obesity and normal weight. Results It was found that unlike SOCS3, which disclosed an elevating expression pattern, the expression level of SOCS1 was lower in the women with obesity as compared with their non-obese counterparts (P-value = 0.03 for SOCS1 transcript level and P-value = 0.011 for SOCS

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Early human evidence such as case series or small samples is exploring possible benefits.

How we grade evidence
HumansObesityInsulinC-Reactive ProteinRNA, MessengerDNA MethylationFemaleSubcutaneous FatSuppressor of Cytokine Signaling 1 ProteinSuppressor of Cytokine Signaling 3 Protein

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research